Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center.

23 Background: Early phase clinical trials usually include patients (pts) with advanced disease who have failed to standard therapies. palliative care (EPC) for these pts has shown improve quality of life and even survival. Pallia 10 score (from 1 10) is a tool developed by the French Palliative Care Society identify best time introduce care. Methods: We assessed other prognostic factors (age, ECOG, Royal Marsden Hospital (RMH) score, LDH albumin levels, number (nb) prior systemic treatments metastatic sites) in enrolled I (P1CT) prospectively during 2 periods (cohort (C1) (C2)). A double-blind assessment was done 15 days member unit C2. > 3 motivated dedicated consultation. Results: From 01/07/2018 01/11/2018 from 01/12/2020 16/04/2021 (C2), total 85 were C1 302 Gastro-intestinal (23%), hematological (14%) lung (11%) cancer most frequent tumor types. similar between both cohorts (Table). On C2, 12% 4% had consultation median referral 18 months (m) after P1CT onset (p = 0.003), 1.5 0.65), respectively. Overall, 75% 76% C2 still alive beyond 3m discontinuation 0.91), followed at least one subsequent treatment 56% 54% pts. In significantly different physician (median 5, range 3-8), 1, -6) nurse 3, 1-8) < 0.001). Conclusions: Only few included referred unit. Median low when which suggests need better implement EPC practice trials.[Table: see text]